Top Markets
#1 Islamic Coin Islamic Coin +152.30%
#2 Bitway Bitway +48.48%
#3 Starpower Starpower +39.10%
#4 aelf aelf +28.38%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +28.38%
#6 SkyAI SkyAI +21.40%
#7 Pons Pons +16.95%
#8 DAPPOS DAPPOS +14.12%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +14.08%
#10 Decred Decred +14.08%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Satsuma Pharmaceuticals, Inc. Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc.

STSA
Rank in Stocks #29900
Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies for the rapid relief of migraines. Its lead therapeutic candidate, STS101, is an integrated drug-device system comprising a proprietary dry-powder formulation of dihydroergotamine mesylate. Currently, STS101 is progressing through its pivotal SUMMIT Phase 3 efficacy trials and is designed for self-administration via a specialized, pre-filled, single-use nasal delivery device. Established in 2016, the company maintains its headquarters in South San Francisco, California.
Share Price
$1.10
Last synced: 2023-06-07
Market Cap
$19.12M
Change (1 day)
-0.90%
Change (1 year)
0.00%
Country
US
Trade Satsuma Pharmaceuticals, Inc. (STSA)

Category

Healthcare
Revenue for Satsuma Pharmaceuticals, Inc. (STSA)
Revenue in Aug 2026 TTM: 0
According to Satsuma Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Satsuma Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR